Keyword: X4 Pharmaceuticals
Alexion replaces CFO Clancy in possible M&A push; Black Diamond nabs three new R&D execs; X4 Pharma founder Skerlj takes on R&D head duties.
X4 Pharmaceuticals has a new R&D chief: Renato Skerlj, who founded the company alongside CEO Paula Ragan and biotech luminary Henri Termeer.
Sudha Parasuraman, formerly of X4, is joining as CMO months before Ribon plans to move its lead drug into phase 1.
Novartis nabs GSK executive for Sandoz CEO; Pfizer oncology executive hops to Aduro as CMO; and Alkermes' former COO will head up ops at Paragon.
Setting the dose of the CXCR4 inhibitor tees X4 up to start the phase 3 portion of the rare immunodeficiency disease trial before the end of the year.
X4 Pharma said the 23% objective response rate was "encouraging" as it was observed in third-line patients, a group whose response rate hovers around 10%.
A pilot showed X4’s anti-PD-1 combination spurred activity in patients that didn’t respond to Opdivo treatment alone, with a drug bought from Sanofi.
The series B equips X4 to move deeper into the clinic on two fronts, with phase 2 and 3 trials in cancers and rare diseases on the horizon.
Yale University has teamed up with cancer biotech X4 Pharma to work on its therapy for WHIM syndrome, a rare genetic disorder.